Dynamics of lipid spectrum indices, endothelial function, and insulin resistance in patients with coronary heart disease in combination with non-alcoholic steatosis

Authors: A. V. Kuriata, M. M. Hrechanyk, DZ «Dnepropetrovsk Medical Academy of the Ministry of Health of Ukraine», Dnipro

The aim of the study was to estimate the effect of ursodeoxycholic acid (UDCA) on the lipid profile, endothelial dysfunction and insulin resistance in patients with coronary heart disease (CHD) in combination with non-alcoholic steatosis.

Materials and methods

The group 1 consisted of 24 patients with CHD and nonalcoholic hepatic steatosis, the group 2 included 18 patients with CHD without hepatic steatosis. The levels of triglycerides (TG), total cholesterol, high-density lipoprotein cholesterol were detected by immunoassay using “Human” (Germany) reagents on the RT-1904C Chemistry Analyzer. The level of plasma insulin was measured by immunoassay using Insulin ELISA, “DRG” (Germany). The functional state of blood vessels endothelium was determined according to the results of reactive hyperemia test. The indicators of insulin resistance was calculated.


Significantly higher levels of TG, insulin resistance and more pronounced endothelial dysfunction indicators in the presence of correlation between the levels of TG with the indexes HOMA1-IR and HOMA2-IR in the group 1 in comparison to the group 2 were found. Decreased levels of TG by 13 % (P = 0.02), low-density lipoprotein cholesterol by 18 % (P = 0.02), very-low-density lipoprotein cholesterol by 42 % (P = 0.02), C-reactive protein by 33 % (P = 0.02) and increased reactive hyperemia index by 35 % (P < 0.05) were revealed in patients with CHD and non-alcoholic steatosis within 2 months of UDCA administration at a dose of 15 mg/kg compared to UDCA untreated patients.


It has been established that the use of UDCA in patients with coronary heart disease and non-alcoholic hepatic steatosis as secondary prevention in cases of statins intolerance can improve the lipid profile, endothelial function and reduce C-reactive protein.

Key words: coronary heart disease, non-alcoholic fatty liver, insulin resistance, lipids, vascular endothelium, ursodeoxycholic acid.


  1. Kuryata, O. V., & Grechanyk, M. M. (2014) Vzaimosvyaz’ lipidnogo spektra krovi, urovnya sistemnogo vospaleniya i massy tela u pacientov s ishemicheskoj bolezn’yu serdca v sochetanii s nealkogol’noj zhirovoj bolezn’yu pecheni i ikh dinamika v usloviyakh vtorichnoj profilaktiki [Interrelation of blood lipid spectrum, level of systemic inflammation and mass of body in patients with coronary heart disease in combination with nonalcoholic fatty liver disease and their dynamics in terms of secondary prevention.]. Medychni perspektyvy, 19(4), 103–111. [in Russian].
  2. Filippova, O. Yu. (2017) Dynamika antropometrychnykh i biokhi­michnykh pokaznykiv pid vplyvom riznykh skhem likuvannia u khvorykh na nealkoholnu zhyrovu khvorobu pechinky u poiednanni z ozhyrin­niam i patolohiieiu biliarnoho traktu [Dynamics of anthropometric and biochemical parameters under the influence of different treatment regimens in patients with non-alcoholic fatty liver disease in combina­tion with obesity and pathology of the biliary tract]. Vrachebnoe delo, 5, 54–61 [in Ukrainian].
  3. Mahmoud, A. A., & Elshazly, S. M. (2014) Ursodeoxycholic Acid Ame­liorates Fructose-Induced Metabolic Syndrome in Rats. PLOS, 9(9), e106993. doi: 10.1371/journal.pone.0106993
  4. Bril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo Sanchez, P., Biernacki, D., et al. (2016) Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. The Journal of Clinical Endocrinology & Metabolism, 101(2), 644–652. doi: 10.1210/jc.2015-3111
  5. Campeau L. (2002) Canadian Cardiovascular Society grading of an­gina pectoris revisited 30 years later. Canadian Journal of Cardiology, 18(4), 439–442.
  6. Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chap­man, M. J., Drexel, H., et al. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37(39), 2999–3058. doi: 1093/eurheartj/ehw272
  7. Celermajer, D. (1997) Endothelial dysfunction: does it matter? It is relevant? Journal American Collage Cardiology, 30(2), 325–333. https:// doi.org/10.1016/S0735-1097(97)00189-7
  8. Ferrannini, E., & Mari, A. (1998) How to measure insulin sensitivity. Hypertension, 16(7), 895–906.
  9. World Health Organisation (2013). Global Health Observatory (GHO): Obesity (2013).
  10. Kim, S. K., Choi, Y. J., Huh, B. W., Park, S. W., Lee, E. J., Cho, Y. W., & Huh, K. B. (2014) Nonalcoholic Fatty liver disease is associated with increased carotid intima-media thickness only in type 2 diabetic subjects with insulin resistance. J Clin Endocrinol Metab, 99(5), 1879–1884. doi: 10.1210/jc.2013-4133
  11. Pasarín, M., Abraldes, J. G., Liguori, E., Kok, B., & La Mura, V. (2017) Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. World J Gastroenterol, 23(37), 6777–6787. doi: 10.3748/wjg.v23.i37.6777
  12. Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., et al. (2011). A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatology, 54(5), 1011–1019. doi: 10.1016/j.jhep.2010.08.030
  13. Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Cat­apano, A. L.,et al. (2016). European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special con­tribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 37(29), 2315–2381. doi: 10.1093/eurheartj/ehw106
  14. Popescu, M., Popescu, I. A., Stanciu, M., Cazacu, S. M., Ianoşi, N. G., Comănescu, M. V., et al. (2016). Non-alcoholic fatty liver disease – clinical and histopathological aspects. Romanian Journal of Morphology and Embryology, 57(4), 1295–1302.
  15. Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., et al. (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology, 140(1), 124–131. doi: 10.1053/j.gastro.2010.09.038
  16. Woollett, L. A., Buckley, D. D., Yao, L., Jones, P. J., Granholm, N. A., Tolley, E. A., & Heubi, J. E. (2003) Effect of ursodeoxycholic acid on cholesterol absorption and metabolism in humans. Journal of Lipid Research, 44(5), 935–942. doi: 10.1194/jlr.M200478-JLR200

Download article in PDF (Ukr)

Аренда яхты